Comparing 2 hypotheses side-by-side
Internalized tau seeds persist in endosomal compartments that acidify via V-ATPase. Endosomal maturation impairment allows tau escape into cytosol via 'back-fusion' or incomplete degradation. TFEB overexpression enhances lysosomal biogenesis and promotes complete tau degradation within lysosomes. However, the autophagy paradox (autophagosomes concentrate substrates and hydrolases, potentially accelerating fibrillization) and lysosomal sieve effect (mature fibrils exceed cathepsin size limits) ar
## Cell-Type Specific TFEB Modulation ### Mechanistic Hypothesis Overview The "Cell-Type Specific TFEB Modulation" hypothesis proposes that the transcription factor EB (TFEB) — the master regulator of autophagy and lysosomal biogenesis — is a high-value therapeutic target for Alzheimer's disease, and that cell-type specific TFEB activation can simultaneously enhance Aβ clearance, tau turnover, and mitochondrial quality control without the toxicity associated with non-selective TFEB activation.
| Dimension | TFEB Activation Clears Tau-Loa | Cell-Type Specific TFEB Modula |
|---|---|---|
| Mechanistic | 0.520 | 0.800 |
| Evidence | 0.580 | 0.700 |
| Novelty | 0.700 | 0.900 |
| Feasibility | 0.500 | 0.600 |
| Impact | 0.620 | 0.800 |
| Druggability | 0.450 | 0.500 |
| Safety | 0.500 | 0.700 |
| Competition | 0.720 | 0.800 |
| Data | 0.600 | 0.600 |
| Reproducible | 0.550 | 0.700 |
No evidence citations yet
No evidence citations yet
4 rounds · quality: 0.73
# Therapeutic Hypotheses: Prion-Like Spreading of Tau Pathology Through Connected Brain Regions ## Hypothesis 1: Exosome-Mediated Transsynaptic Tau Propagation via LRP1 Receptor Targeting **Title:**...
# Critical Evaluation of Tau Spreading Hypotheses ## Hypothesis 1: LRP1-Mediated Exosomal Tau Uptake ### Weak Links **Receptor Specificity Problem:** LRP1 is a multiligand receptor recognizing >40 ...
# Feasibility Assessment: Prion-Like Tau Spreading Hypotheses ## Executive Summary After integrating the theorist's mechanistic proposals with the skeptic's counterarguments, the seven hypotheses sp...
```json { "ranked_hypotheses": [ { "title": "CDK5 Inhibition at Presynaptic Terminals Prevents Activity-Dependent Tau Release and Transsynaptic Propagation", "description": "Neuronal...
4 rounds · quality: 0.95
Based on my comprehensive research, I'll now generate novel therapeutic hypotheses that address the causation vs. compensation debate around TFEB in neurodegeneration: ## Novel Therapeutic Hypotheses...
## Critical Evaluation of TFEB Therapeutic Hypotheses Based on my analysis, I'll provide a rigorous critique of each hypothesis, identifying significant weaknesses and gaps in the evidence base. ###...
# Practical Feasibility Assessment: TFEB Therapeutic Hypotheses ## Executive Summary Most of these TFEB hypotheses face significant druggability challenges and lack validated chemical matter. Only 2...
```json { "ranked_hypotheses": [ { "title": "TFEB-Independent Autophagy Bypass", "description": "Direct activation of downstream autophagy effectors (ULK1/ULK3, ATG proteins) or mTOR...
Curated mechanism pathway diagrams from expert analysis
graph TD
subgraph Disease["Alzheimer's Disease Pathology"]
A["Amyloid beta accumulation"] -->|"impairs"| B["Lysosomal dysfunction"]
C["Tau protein aggregation"] -->|"disrupts"| B
B -->|"reduces"| D["TFEB nuclear translocation"]
D -->|"decreases"| E["CLEAR gene network expression"]
E -->|"impairs"| F["Autophagy and proteostasis"]
F -->|"worsens"| G["Neuronal degeneration"]
end
subgraph Intervention["Cell-Type Specific TFEB Modulation"]
H["AAV vector delivery"] -->|"targets"| I["Neuron-specific promoter"]
H -->|"targets"| J["Microglia-specific promoter"]
I -->|"expresses"| K["Constitutively active TFEB"]
J -->|"expresses"| K
K -->|"translocates to"| L["Nucleus"]
end
subgraph Mechanisms["Molecular Mechanisms"]
L -->|"activates"| M["CLEAR gene network"]
M -->|"upregulates"| N["Lysosomal biogenesis"]
M -->|"enhances"| O["Autophagy machinery"]
N -->|"increases"| P["Protein degradation capacity"]
O -->|"promotes"| P
end
subgraph Outcomes["Therapeutic Outcomes"]
P -->|"clears"| Q["Amyloid beta plaques"]
P -->|"degrades"| R["Tau aggregates"]
P -->|"improves"| S["Mitochondrial quality control"]
Q -->|"leads to"| T["Neuroprotection"]
R -->|"leads to"| T
S -->|"leads to"| T
end
style A fill:#ef5350,stroke:#333,color:#000
style C fill:#ef5350,stroke:#333,color:#000
style B fill:#ef5350,stroke:#333,color:#000
style G fill:#ef5350,stroke:#333,color:#000
style H fill:#81c784,stroke:#333,color:#000
style I fill:#81c784,stroke:#333,color:#000
style J fill:#81c784,stroke:#333,color:#000
style K fill:#ce93d8,stroke:#333,color:#000
style D fill:#4fc3f7,stroke:#333,color:#000
style L fill:#4fc3f7,stroke:#333,color:#000
style M fill:#4fc3f7,stroke:#333,color:#000
style N fill:#4fc3f7,stroke:#333,color:#000
style O fill:#4fc3f7,stroke:#333,color:#000
style P fill:#4fc3f7,stroke:#333,color:#000
style E fill:#4fc3f7,stroke:#333,color:#000
style F fill:#4fc3f7,stroke:#333,color:#000
style Q fill:#ffd54f,stroke:#333,color:#000
style R fill:#ffd54f,stroke:#333,color:#000
style S fill:#ffd54f,stroke:#333,color:#000
style T fill:#ffd54f,stroke:#333,color:#000